Phio Price To Sales Ratio vs Payables Turnover Analysis

PHIO Stock

USD 2.53 0.15 6.30%

Phio Pharmaceuticals financial indicator trend analysis is much more than just breaking down Phio Pharmaceuticals Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Phio Pharmaceuticals Corp is a good investment. Please check the relationship between Phio Pharmaceuticals Price To Sales Ratio and its Payables Turnover accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Phio Pharmaceuticals Corp Price To Sales Ratio account and Payables Turnover. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Phio Pharmaceuticals' Price To Sales Ratio and Payables Turnover is -0.27. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Payables Turnover in the same time period over historical financial statements of Phio Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Phio Pharmaceuticals' Price To Sales Ratio and Payables Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Phio Pharmaceuticals Corp are associated (or correlated) with its Payables Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Payables Turnover has no effect on the direction of Price To Sales Ratio i.e., Phio Pharmaceuticals' Price To Sales Ratio and Payables Turnover go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Phio Pharmaceuticals Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Phio Pharmaceuticals sales, a figure that is much harder to manipulate than other Phio Pharmaceuticals Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most indicators from Phio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Phio Pharmaceuticals Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

At this time, Phio Pharmaceuticals' Issuance Of Capital Stock is very stable compared to the past year. As of the 22nd of November 2024, Sales General And Administrative To Revenue is likely to grow to 211.86, while Selling General Administrative is likely to drop about 4.2 M.

	2023	2024 (projected)
Reconciled Depreciation	187K	117.1K
Non Recurring	4.2M	3.8M

Reconciled Depreciation Non Recurring

Phio Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Non Currrent Assets Other
Total Assets		-0.05	0.65	0.62	0.9	0.01	0.25	-0.97	-0.58	0.03	0.97	0.07	1.0	-0.04	-0.59	0.3	-0.1	0.48	0.64	-0.02	0.02	1.0	0.27	-0.59	-0.04	0.33
Short Long Term Debt Total	-0.05		-0.05	0.07	0.09	0.45	-0.34	0.07	0.37	0.06	-0.1	0.5	-0.06	0.66	-0.17	-0.72	-0.22	-0.26	-0.18	-0.25	-0.57	-0.06	0.27	-0.17	0.66	0.28
Other Current Liab	0.65	-0.05		0.84	0.58	-0.21	0.27	-0.63	-0.29	-0.1	0.62	-0.14	0.66	-0.02	-0.32	0.14	-0.11	0.14	0.34	0.0	-0.12	0.66	0.0	-0.32	-0.02	0.26
Total Current Liabilities	0.62	0.07	0.84		0.63	0.1	0.4	-0.56	-0.3	0.16	0.57	0.2	0.62	-0.01	-0.31	0.12	-0.33	0.1	0.33	-0.2	-0.03	0.61	-0.18	-0.31	-0.01	0.19
Total Stockholder Equity	0.9	0.09	0.58	0.63		0.11	0.53	-0.87	-0.7	0.26	0.88	0.17	0.89	-0.06	-0.69	0.37	-0.52	0.5	0.79	-0.46	0.13	0.89	0.02	-0.69	-0.06	0.4
Property Plant And Equipment Net	0.01	0.45	-0.21	0.1	0.11		0.07	-0.03	0.01	0.02	0.04	0.97	-0.02	0.47	-0.03	-0.25	-0.17	0.13	0.12	-0.19	-0.05	-0.01	-0.1	-0.03	0.47	-0.22
Current Deferred Revenue	0.25	-0.34	0.27	0.4	0.53	0.07		-0.24	-0.74	0.5	0.28	0.07	0.23	-0.51	-0.31	0.72	-0.76	0.47	0.67	-0.71	0.65	0.25	-0.69	-0.31	-0.51	0.02
Net Debt	-0.97	0.07	-0.63	-0.56	-0.87	-0.03	-0.24		0.58	0.06	-1.0	-0.1	-0.97	-0.01	0.6	-0.29	0.09	-0.47	-0.67	0.02	0.0	-0.97	-0.24	0.6	-0.01	-0.41
Retained Earnings	-0.58	0.37	-0.29	-0.3	-0.7	0.01	-0.74	0.58		-0.36	-0.61	0.0	-0.57	0.5	0.75	-0.79	0.5	-0.68	-0.95	0.45	-0.63	-0.57	0.13	0.75	0.5	-0.07
Accounts Payable	0.03	0.06	-0.1	0.16	0.26	0.02	0.5	0.06	-0.36		-0.05	0.11	0.03	-0.1	-0.16	0.12	-0.53	0.08	0.32	-0.52	0.14	0.03	-0.48	-0.16	-0.1	0.25
Cash	0.97	-0.1	0.62	0.57	0.88	0.04	0.28	-1.0	-0.61	-0.05		0.1	0.97	-0.05	-0.61	0.33	-0.11	0.48	0.68	-0.03	0.05	0.97	0.22	-0.61	-0.05	0.39
Non Current Assets Total	0.07	0.5	-0.14	0.2	0.17	0.97	0.07	-0.1	0.0	0.11	0.1		0.03	0.52	-0.1	-0.3	-0.21	0.09	0.14	-0.22	-0.11	0.04	-0.1	-0.1	0.52	-0.07
Cash And Short Term Investments	1.0	-0.06	0.66	0.62	0.89	-0.02	0.23	-0.97	-0.57	0.03	0.97	0.03		-0.04	-0.59	0.29	-0.08	0.45	0.63	0.0	0.0	1.0	0.28	-0.59	-0.04	0.36
Net Receivables	-0.04	0.66	-0.02	-0.01	-0.06	0.47	-0.51	-0.01	0.5	-0.1	-0.05	0.52	-0.04		0.24	-0.83	0.2	-0.28	-0.25	0.14	-0.85	-0.05	0.2	0.24	1.0	0.21
Common Stock Total Equity	-0.59	-0.17	-0.32	-0.31	-0.69	-0.03	-0.31	0.6	0.75	-0.16	-0.61	-0.1	-0.59	0.24		-0.41	0.43	-0.44	-0.78	0.39	-0.31	-0.59	-0.34	1.0	0.24	-0.28
Common Stock Shares Outstanding	0.3	-0.72	0.14	0.12	0.37	-0.25	0.72	-0.29	-0.79	0.12	0.33	-0.3	0.29	-0.83	-0.41		-0.34	0.63	0.64	-0.29	0.87	0.3	-0.2	-0.41	-0.83	-0.25
Non Current Liabilities Total	-0.1	-0.22	-0.11	-0.33	-0.52	-0.17	-0.76	0.09	0.5	-0.53	-0.11	-0.21	-0.08	0.2	0.43	-0.34		-0.18	-0.52	0.99	-0.34	-0.1	0.52	0.43	0.2	-0.23
Other Current Assets	0.48	-0.26	0.14	0.1	0.5	0.13	0.47	-0.47	-0.68	0.08	0.48	0.09	0.45	-0.28	-0.44	0.63	-0.18		0.69	-0.17	0.51	0.48	0.13	-0.44	-0.28	-0.34
Other Stockholder Equity	0.64	-0.18	0.34	0.33	0.79	0.12	0.67	-0.67	-0.95	0.32	0.68	0.14	0.63	-0.25	-0.78	0.64	-0.52	0.69		-0.5	0.45	0.64	-0.07	-0.78	-0.25	0.17
Total Liab	-0.02	-0.25	0.0	-0.2	-0.46	-0.19	-0.71	0.02	0.45	-0.52	-0.03	-0.22	0.0	0.14	0.39	-0.29	0.99	-0.17	-0.5		-0.31	-0.01	0.51	0.39	0.14	-0.22
Property Plant And Equipment Gross	0.02	-0.57	-0.12	-0.03	0.13	-0.05	0.65	0.0	-0.63	0.14	0.05	-0.11	0.0	-0.85	-0.31	0.87	-0.34	0.51	0.45	-0.31		0.02	-0.29	-0.31	-0.85	-0.38
Total Current Assets	1.0	-0.06	0.66	0.61	0.89	-0.01	0.25	-0.97	-0.57	0.03	0.97	0.04	1.0	-0.05	-0.59	0.3	-0.1	0.48	0.64	-0.01	0.02		0.27	-0.59	-0.05	0.34
Short Term Debt	0.27	0.27	0.0	-0.18	0.02	-0.1	-0.69	-0.24	0.13	-0.48	0.22	-0.1	0.28	0.2	-0.34	-0.2	0.52	0.13	-0.07	0.51	-0.29	0.27		-0.34	0.2	-0.09
Common Stock	-0.59	-0.17	-0.32	-0.31	-0.69	-0.03	-0.31	0.6	0.75	-0.16	-0.61	-0.1	-0.59	0.24	1.0	-0.41	0.43	-0.44	-0.78	0.39	-0.31	-0.59	-0.34		0.24	-0.28
Other Liab	-0.04	0.66	-0.02	-0.01	-0.06	0.47	-0.51	-0.01	0.5	-0.1	-0.05	0.52	-0.04	1.0	0.24	-0.83	0.2	-0.28	-0.25	0.14	-0.85	-0.05	0.2	0.24		0.21
Non Currrent Assets Other	0.33	0.28	0.26	0.19	0.4	-0.22	0.02	-0.41	-0.07	0.25	0.39	-0.07	0.36	0.21	-0.28	-0.25	-0.23	-0.34	0.17	-0.22	-0.38	0.34	-0.09	-0.28	0.21

Click cells to compare fundamentals

Phio Pharmaceuticals Account Relationship Matchups

Phio Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.0M	15.7M	25.2M	12.8M	9.4M	12.4M
Other Current Liab	27K	1.2M	2.5M	890K	907K	1.2M
Total Current Liabilities	1.9M	2.2M	3.1M	1.8M	1.6M	2.2M
Total Stockholder Equity	5.7M	13.0M	21.9M	10.8M	7.7M	8.1M
Property Plant And Equipment Net	721K	557K	416K	344K	39K	37.1K
Net Debt	(6.4M)	(13.6M)	(23.8M)	(11.5M)	(8.5M)	(8.9M)
Retained Earnings	(94.8M)	(103.6M)	(116.9M)	(128.4M)	(139.2M)	(132.2M)
Accounts Payable	809K	728K	283K	779K	657K	647.1K
Cash	6.9M	14.2M	24.1M	11.8M	8.5M	10.8M
Non Current Assets Total	739K	575K	443K	368K	42K	39.9K
Cash And Short Term Investments	6.9M	14.2M	24.1M	11.8M	8.5M	11.5M
Common Stock Shares Outstanding	38.4K	42.4K	118.7K	126.2K	231.5K	243.1K
Liabilities And Stockholders Equity	8.0M	15.7M	25.2M	12.8M	9.4M	12.4M
Other Current Assets	316K	920K	670K	665K	832K	489.5K
Other Stockholder Equity	100.6M	116.6M	138.8M	139.2M	146.9M	88.9M
Total Liab	2.3M	2.7M	3.2M	2.0M	1.6M	3.1M
Property Plant And Equipment Gross	721K	557K	416K	344K	1.2M	1.2M
Total Current Assets	7.3M	15.2M	24.7M	12.4M	9.3M	12.1M
Property Plant Equipment	172K	210K	557K	416K	478.4K	268.2K
Net Tangible Assets	13.6M	5.7M	13.0M	21.9M	25.2M	26.5M
Retained Earnings Total Equity	(78.6M)	(85.9M)	(94.8M)	(103.6M)	(93.3M)	(97.9M)
Capital Surpluse	80.4M	99.5M	100.6M	116.6M	134.1M	86.0M
Net Invested Capital	5.7M	13.2M	21.9M	10.8M	7.7M	11.8M
Net Working Capital	5.4M	13.0M	21.7M	10.5M	7.7M	11.5M

Pair Trading with Phio Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Phio Stock

0.31

MDGL

Madrigal Pharmaceuticals

Pair Corr

The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.

The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:

How To Invest In Phio

Details

Is Phio Stock a good investment?

Details

What is Phio Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(14.81)

Return On Assets

(0.61)

Return On Equity

(1.27)

The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Phio Price To Sales Ratio vs Payables Turnover Analysis

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Payables Turnover

Phio Pharmaceuticals fundamental ratios Correlations

Phio Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Phio Pharmaceuticals fundamental ratios Accounts

Pair Trading with Phio Pharmaceuticals

Moving against Phio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Liab	+ 1.0	Net Receivables
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 0.99	Non Current Liabilities Total

Cash	- 1.0	Net Debt
Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Other Stockholder Equity	- 0.95	Retained Earnings
Net Debt	- 0.87	Total Stockholder Equity